Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Shares of Eli Lilly & Co. erased gains to trade down nearly 1% after White House press secretary Karoline Leavitt said the company was among 17 drugmakers that will be receiving letters from President ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

Eli Lilly’s blockbuster diabetes drug Mounjaro matched the ability of an older treatment to prevent major heart complications ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...